Abstract
The United Arab Emirates (UAE) is one of the fastest growing economies with consequent increase in non-communicable diseases including cancer. The number of reported cases and mortality have been increasing in the UAE over the years, despite screening and early detection efforts which appear to be far from target coverage of the intended population. In this work, we highlight key elements of a proposed national cancer control plan for the UAE. The plan is still a work in progress and has not yet been officially adopted. A comprehensive and effective control plan requires accurate data, a reliable cancer registry, and periodic monitoring and evaluation. The UAE cancer control plan is being prepared in line with the WHO and EMRO framework, with defined objectives and goals. The objectives are to combat cancer, reduce incidence, control mortality, and improve outcomes and quality of life for cancer patients. There is also a focus on improving public health education, prevention, early detection, prompt diagnosis, treatment facilitation, continuity of care, performance evaluation, training of workforce, and research.
Keywords: cancer control, prevention, middle east, arab, registry
1. Introduction
Cancer is a major health problem globally, and the second leading cause of death in the world, with a mortality rate of 8.8 million people in 2015, accounting for approximately 1 out of 6 deaths [1]. Cancer is the fourth leading cause of death in the Eastern Mediterranean region, after cardiovascular diseases, infectious diseases, and trauma [2]. The rate of cancer appears to be increasing in the Middle East, mostly related to rapid population growth, increasing life expectancy, and urbanization with progressively westernized lifestyles [3]. The incidence of cancer is predicted to double in the next two decades, the highest expected increase among all WHO regions. It is expected that by 2030, cancer related deaths will reach 652,097 from 367,441 reported in 2012 [4]. These projections are based on the impact of population growth and aging, the additive effect of increased exposure to cancer risk factors, such as smoking, diet, physical inactivity, and environmental pollution, which would lead to a greater rise in cancer burden. This employs an enormous burden on healthcare services.
Cancer is the third leading cause of death in the United Arab Emirates (UAE) after cardiovascular diseases and trauma. In the UAE, the mortality-to-incidence ratio is 0.39, which is comparable to most developed countries (approximately 0.38). The crude cancer death rate is 10.26/100,000 people, with breast cancer ranking first (110 deaths), while colon cancer ranking second (98 deaths), and lung cancer ranking third (80 deaths) [5,6,7].
Cancer is a preventable disease in a significant number of cases. A substantial number of cancers can be detected in early stages and treated successfully. Even if diagnosed in late stages, cancer pain can be decreased, the disease progression slowed down, quality of life improved, and patients and their families facilitated to cope. Effective cancer control plans are, therefore, indispensable everywhere. In most countries, irrespective of economic status, some level of cancer control activity is ongoing. In many countries, there is no effective cancer control plan, the plan is out of date, or is not effectively implemented. There is thus a need for a comprehensive plan, its effective implementation, regular monitoring, quality assurance, and updating as per local needs and requirement [1,2,4].
Cancer, today, is managed by a multidisciplinary integrated approach with equity and uniform accessibility. The UAE aims to reduce the burden of cancer in the UAE and to make all possible efforts to deliver optimal cancer care for cancer patients and their families. It also aims to expand cancer care services in the UAE in line with international guidelines and the best global practices, adjusted to suit the needs of the country [3,6,7].
In this work we highlight key elements of a proposed national cancer control plan for the UAE. The plan is still work in progress and has not been yet officially adopted.
2. Cancer Burden in the UAE
During the mid-twentieth century, the UAE rose to become one of the fastest growing economies globally [8,9]. This growth leads to economic, sociodemographic, and lifestyle changes of the population, paralleled by an epidemiological increase in the rates of non-communicable diseases (NCD) and cancer. Subsequent studies in the UAE linked this increase in cancer with an exposure to several risk factors, including physical inactivity and sedentary lifestyles [10,11,12], the consumption of high-caloric and poorly nutritive meals [13], an increase in obesity [12,13], an increase in smoking [14], and elevated air pollutant levels [15]. There is an impact of improved cancer diagnostics. The reported deaths due to NCD in 2016 were 77.3% of all deaths. The main causes of deaths are cardiovascular diseases (40%) and cancer (12%). Communicable, maternal, perinatal, and nutritional conditions cause around 6% of all deaths, while chronic respiratory diseases and diabetes represent about 5% each [9,11].
2.1. Cancer Incidence Rate
A total of 4299 cases were diagnosed in 2017 in the UAE, including 4123 (95.91%) invasive cancer cases and 176 (4.09%) in situ cases. There were 2370 (55.1%) females and 1929 (44.9%) male. The cancer cases reported in 2016 were 4210 indicating a rise in 2017 from 2016, as per data of the annual reports of the National Cancer Registry in the United Arab Emirates. Invasive cancer cases are distributed according to the nationality in 2017, with 680 (62%) female cases and 425 (38%) male cases among UAE citizens, and 1570 (52%) female cases and 1448 (48%) male cases in non-UAE citizens [3,5,6].
2.2. The Most Common Cancer Types
The frequency of cancers in males and females as reported from the UAE in 2017 are summarized in Table 1. Breast is the most common site of cancer among the population of the UAE, accounting for 20.23% of all cancer cases in the year 2017. After breast cancer, colorectal cancer (10.24%), thyroid cancer (9.99%), leukemia (7.62%), skin (5.04%), non-Hodgkin’s lymphoma (4.17%), and prostate cancer (3.76%) are the most common types of cancers in UAE [3,6].
Table 1.
|
|
||
|---|---|---|---|
| Cancer Type | No. of Cases and % | Cancer Type | No. of Cases and % |
| Colorectal | 256 (13.67%) | Breast | 825 (36.67%) |
| Leukemia | 196 (10.46%) | Thyroid | 302 (13.42%) |
| Prostate | 155 (8.28%) | Colorectal | 166 (7.38%) |
| Skin | 134 (7.15%) | Leukemia | 118 (5.24%) |
| Lip, Oral cavity and Pharynx | 112 (5.98%) | Uterus | 111 (4.93%) |
| Thyroid | 110 (5.87%) | Cervix uteri | 82 (3.64%) |
| Non-Hodgkin Lymphoma | 107 (5.71%) | Skin | 74 (3.29%) |
| Bronchus and Lung | 103 (5.50%) | Ovary | 70 (3.11%) |
| Urinary bladder | 91 (4.86%) | Non-Hodgkin Lymphoma | 65 (2.89%) |
| Stomach | 59 (3.15%) | Lip, Oral cavity, and Pharynx | 39 (1.73%) |
Table 2 shows the most common pediatric cancers in the UAE. Leukemia was the most common cancer among children in the UAE in 2017, accounting for 41.8% of all cancer cases in children [3,5,6].
Table 2.
| Cancer Type | No. of Cases and % |
|---|---|
| Leukemia | 61 (41.8%) |
| Kidney and Renal pelvis | 11 (7.5%) |
| Non-Hodgkin Lymphoma | 10 (6.8%) |
| Liver and intrahepatic bile ducts | 8 (5.5%) |
| Brain and CNS | 7 (4.8%) |
2.3. Cancer Mortality
In 2017, cancer-related deaths in the UAE reached 955, about 10.82% of total deaths. The crude cancer death rate was 10.26/100,000 people, with breast cancer ranked first (110 deaths), while colon cancer ranked second (98 deaths), lung cancer ranked third (80 deaths), and leukemia ranked fourth (52 cases). The number of cancer deaths shows that the percentage of cancer deaths increased during the year per one thousand of the population in 2018 compared to 2017, which was adopted as a baseline for the index targets [3,6,7].
2.4. Cancer Prevention, Screening, and Early Detection
Around one third of cancers can be preventable by changes in lifestyle, genetic testing of high-risk groups, and vaccination. Even though cancer incidence is relatively low in the UAE, we must focus on improving the outcome of patients being treated for cancer. Nothing impacts cancer survival rates more than screening and early detection. Early detection of cancer is known to increase the chance of a successful treatment and improved outcome. Results for 2017 show a lower rate of population coverage for early cancer screening among the target age groups [<70%] than the targets set nationally or by the World Health Organization (Table 3) [1,2,4,5,16].
Table 3.
Screening targets and performance compared to the targets set nationally or by the World Health Organization (WHO), based on unpublished data from the Ministry of Health and Prevention.
| Type of Cancer | Target Age Group | Examination | % Of the Population Eligible for Screening Target Age Group | 2017 Investigated Result | Population Coverage Ratio for Target Groups |
|---|---|---|---|---|---|
| Breast | Female ≥ 40 years | Mammogram every two years | 50% | 20,752 | 6.68% |
| Colon | Females and males ≥ 40–75 years | FIT Test after every 2 years | 50% | 18,399 | 1.6% |
| Cervix | Females All sexually active females, symptom free, aged 25–65 years | Cervical pap smear test should be after every 3 years | 33% | 39,281 | 7% |
The causes of low screening rates in the UAE population and some actions recommended/proposed to improve these rates are described in Table 4 [5,6].
Table 4.
Causes and reformatory actions to improve screening rates in the UAE.
| Cause/Factor | Root Causes | Reformatory Actions |
|---|---|---|
| Access to the service |
|
|
| Mechanism and quality control of cancer screening services |
|
|
| Community awareness for the importance of early examination and Detection of Cancer |
|
|
| End User factors influencing the screening and detection service |
|
|
| Capacity Building in Human Resources and Logistic Support |
|
|
2.5. Diagnostic Services
A swift and definitive diagnosis is the key to prompt and definite treatment. We lack efficient and well-developed pathways to ensure that patients are referred to an appropriate physician and centers in time to be diagnosed within a minimum possible time. During this timeframe, patients are expected to complete a clinical physical assessment, radiologic imaging, and tissue diagnosis by biopsy and pathology. The plan for further assessment or management must be discussed and approved at multi-disciplinary team (MDT) tumor board meetings. All diagnostic services are not available universally and with the desired equity. We need tumor site-specific diagnostic clinics with a facility to support genetic testing. We will have to ensure quality assurance with international standards and quality control regulations, often requiring accreditation with recognized international organizations. This should come with regulation, development, and implementation of established diagnostic standards [5,17,18,19,20,21].
2.6. Cancer Management
It is a must to establish, improve, sustain, and monitor all-inclusive cancer services, including surgical oncology, medical oncology, radiation oncology, pediatric oncology, and palliative care services. There are newer sub-specialties evolving as gynecologic oncology, uro-oncology, osteo-oncology, neuro-oncology, among others. There is forthcoming necessity and demand to develop these specialized cancer care services with excellence, which are not up to the mark at present, nor in a true construct. We lack well-organized supportive services available to each and every patient such as clinical psychologist, clinical dietitians, social workers, and community nursing services at all levels of care provision. We are still far-away from perfection to develop and implement practice guidelines for referring physicians, radiologists, and pathologists for each cancer. These need to be formulated as per our local data, our set objectives and settings, local disease biology, and access to resources. It is essential to strengthen the role of the MDT tumor boards in cancer institutes and all new cases as well as complex cases must be reviewed and discussed by a MDT, to arrive at a well-documented plan of care for each individual [17,18,19,20,21]. Palliative care services are only available in comprehensive care centers.
2.7. Cancer Research
Overall, cancer research productivity is evolving over time, although several evidence gaps continue to persist. The scope for basic and translational research is generally expanding within the country with the continued rise in the number academic institutions and research programs dedicated to molecular and cellular research. Observational studies have been mostly focused on screening and basic parameters of epidemiology. Future directions should focus on expansion of national registries and longitudinal collection of clinically relevant variables that can better inform the clinical and molecular profiles of breast cancer in the country, and, more importantly, survival metrics that can help inform management strategies. Lastly, there is an evident paucity of therapeutic clinical trials, which is a challenge shared by the wider region. Several efforts are currently ongoing to solidify partnerships with clinical trial sponsors to host interventional studies in the country, considering the regulatory and resource infrastructures are well advanced and adaptable to international standards and requirements. There has to also be an equal effort placed on understanding modifiable lifestyle risk factors for cancer, such as smoking, obesity, diet, and physical inactivity, which are perceived to be in ‘bad shape’ in the UAE although true prevalence rates in Emiratis vs. expats and associations with cancer incidence remain unclear.
3. The UAE Cancer Control Plan
In 2011 [11,22,23], the WHO proclaimed the crucial demand to create a baseline for monitoring trends and to assess the progress of countries to contest the global epidemic of cancer in confronting this scourge. A cancer control plan needs accurate data assimilation, a consistent and progressive cancer registry, and monitoring and appraisal initiatives to ensure appropriate priority settings and to ensure quality [24]. The WHO advised governments to consolidate their health information systems with reliable and evidence-based research indicators.
The Ministry of Health and Prevention with its partners in the UAE started developing a national cancer control plan to be implemented in accordance with specific objectives. The plan, presented herein, is still a work in progress and has not been officially adopted. The proposed plan covers the years 2022–2026 and was prepared focused on the global action plan for prevention and control of cancer by the WHO and the regional executive framework for prevention and control of cancer for the Eastern Mediterranean Region (EMRO). The outline of this plan reflects the directions and strategy to reduce the cancer incidence and facilitate journey of cancer patients through their disease course, decrease mortality by at least 25%, and improve the quality of life through an integrated approach based on comprehensive activities and cancer care services. The plan is based on nine strategic axes centered across the healthcare system, services, prevention, sustainability, and innovation. It includes areas of governance, prevention, early examination, treatment, palliative care, surveillance, and research [2,6,16].
Development of the plan was made through a committee of local oncology practitioners and policy makers in co-operation with various stakeholders including both public and private sectors involved in clinical care and public health and education; to enrich commitment to global and regional initiatives to fight and control cancer. The plan is a strategic and general framework for the determinants and controls used in formulating policies, developing legislation, and assessing material resources to support the prevention, care, and management programs in the UAE. It further proposed appropriate measures for implementing the plan, continuous monitoring, and a follow-up system. Measurement indicators to evaluate the efficacy of suggested and adopted activities were also established. It represents the roadmap for the implementation of specifics of the plan for the prevention and control of cancer. This plan is aligned with the National Agenda of the UAE for 2021 and aims to reduce cancer death rates which will help achieve the objectives of the agenda [11,21,23,24]. The vision, objectives and strategy of the proposed UAE cancer control plan are summarized in Table 5.
Table 5.
Vision, objectives, and strategy of the UAE cancer control plan.
| Vision | To reduce deaths through multiple interventions including early detection of cancer in the UAE |
| Message | We fight cancer in the UAE hand in hand with our partners and work with innovation and exercising best practices. We are embarking to assemble comprehensive competencies and human resources for a disease-free UAE society |
| Objectives of the Strategy | 1. To strengthen the planning and implement it at the national level to combat cancer in the United Arab Emirates 2. To reduce premature and preventable deaths and the risk of developing cancer by 25% by the year 2025 3. To strengthen cancer prevention, early detection, and treatment 4. To ensure sustainability and continuous development of cancer prevention, control, and treatment strategies 5. To enhance the quality of life for cancer patients 6. To ensure continuum of care through well-defined transition points in the healthcare system 7. To develop a framework to enhance, integrate, and coordinate initiatives to combat cancer and outline principles and regulations to supervise the organization 8. To ensure consistency and standardization in practices and help unify efforts in the fight against cancer 9. To consolidate the efforts by providing a legal framework of applicable governmental regulations and policies |
3.1. The Guiding Principles and Strategic Directions of the UAE Cancer Control Plan as per WHO and EMRO Guidelines
The national cancer control plan is based on the strategic directions set by the executive framework of the action plan as pronounced by the World Health Organization for the Eastern Mediterranean Region. The recommendations of WHO and EMRO are summarized in Table 6 [4,11,16,24].
Table 6.
Recommendations of WHO and EMRO for cancer control plans.
| 1. | Governance: Focus on developing a strategy and a multi-sectoral committee for the prevention and control of cancer; while ensuring the availability of a sustained budget, adequate national cancer rates, setting costs for care and treatment packages, and determining a mechanism to cover treatment expenses with equity |
| 2. | Prevention: Focus on adopting healthy life by combating smoking, encouraging physical activity, and healthy food in line with the Non-Communicable Disease control framework/plan. The focus should include vaccinations against hepatitis and HPV |
| 3. | Early detection: The strategic directions in this area are based on four axes: Awareness of the population about early warning signs and symptoms of cancer, education, continuing education for health staff on the early signs and symptoms of the common cancers, prompt diagnosis and referral for patients, screening programs, and a continuous evaluation of the effectiveness of these programs. The focus should also be employed on accessibility and the affordability of diagnostic tests for suspected cases. |
| 4. | Treatment: Focus on developing and implementing protocols and best clinical practices based on evidence-based guidelines. Assess human resource needs and focus on accessibility and affordability of cancer care services and extend affordable treatment packages. This must also include the development of integrated, coordinated and prompt referral systems to avoid delays in diagnosis and treatment. |
| 5. | Palliative care: There is a need to develop integrated multidisciplinary palliative care services including pain care and psychological support, available in hospitals and primary healthcare centers. Developing and implementing protocols for best evidence based clinical practice and integrated care, and a swift and early transition. Palliative care should be included in medical academic programs. |
| 6. | Research and Surveillance: Develop a population based national cancer registry, hospital registries, and monitor these with an accredited quality assurance program. The area includes focusing on developing and implementing an integrated plan for research according to the priorities of the country. |
3.2. Definitions of the Strategic Axes and Executive Framework of the UAE Cancer Control Plan
The UAE cancer control plan should include 3 pivotal focus areas concentrated around nine strategic axes (Table 7).
Table 7.
Strategic axes of the UAE cancer control plan.
| First Area |
|---|
| 1. Education and understanding |
| Enhancing health awareness about the knowledge of cancer, risk factors leading to cancer and correction of misconceptions about the disease |
| 2. Prevention |
| Launching awareness campaigns and prevention programs against cancer and known causes |
| 3. Early detection |
| Detecting cancer in the early stages to increase the patients’ survival and outcome. It involves periodic clinical assessments and reduces the delays in appropriate treatment referrals to receive treatment promptly |
| 4. Rapid diagnosis |
| A healthcare center should assess condition of the patient promptly in a systematic integrated way and take appropriate medical decisions based on a developed pathway |
| Second Area |
| 5. Treatment |
| Provide appropriately validated clinical practices in line with international guidelines for treating cancer according to disease stage to improve outcomes |
| 6. Ongoing care |
| Provide timely transition to post-treatment and palliative care services for cancer patients and educating them about the appropriate ways to live with the disease and directions to avoid disease recurrence |
| Third Area |
| 7. Performance measurements |
| Establishing national records including all data sources in a central place and assemble comprehensive data of high quality, accuracy, and to record information about a disease |
| 8. Workforce capacity building |
| Providing a qualified and appropriately trained team to deliver prevention, treatment, continuity of care for patients; and provision of suitable training facilities for the workforce |
| 9. Research |
| Cancer research improves the diagnosis, treatment, outcome, and enhance quality of life by translating quality research and clinical trials for improvements in personalized care |
The first is prevention, which revolves around the axes of education, understanding, prevention and detection, early and rapid diagnosis. The second focused area is that of healthcare and services which includes the axes of treatment and continuous care. The third area is that of sustainability and innovation and revolves around the axes of performance measurement, workforce, and research. These are further detailed and explained in depth in Table 8.
Table 8.
Detailed strategic and executive framework of the UAE cancer control plan.
| Strategic Axis | I. Education and Understanding | |||
|---|---|---|---|---|
| Main objectives | Application mechanisms | Measurement indicators | The executing agency | Follow-up |
| Raising health awareness about cancer and associated risk factors and correcting the misconceptions | Conducting a national survey on awareness in society assessing knowledge of risk factors and opinions about access to services and early examination | Survey completion rate | Ministry of Health and Protection (Department of Specialized Care) |
Ministry of Health and Protection (Department of Specialized Care) |
Raising health awareness about cancer risk factors
|
Number of awareness campaigns | Stakeholders | ||
| Awareness campaigns synchronized with designated international days for each cancer type | Number of awareness campaigns | Stakeholders | ||
| Strategic Axis | Ⅱ. Prevention | |||
| Main objectives | Application mechanisms | Measurement indicators | The executing agency | Follow-up |
| Monitoring of risk factors between different groups in society and encouragement to adopt healthy lifestyles | Physical activity
|
The number of awareness programs | Ministry of Health and Prevention /Care department Specialization/Promotion of health management in participating parties |
Ministry of Health and Prevention |
Healthy foods
|
The number of awareness programs | |||
| Assessment of the presence of carcinogenic factors in the environment and highlighting the environmental pollution and exposure to radiation | The number of awareness programs | |||
| Awareness campaigns about the harms of smoking and shisha in young people | The number of awareness programs Monitor smoking rates |
|||
| Providing preventive vaccinations | Hepatitis B vaccination for prevention of liver cancer for high-risk population | Hepatitis C vaccination coverage rate Children and among those who have major risk |
Ministry of Health and Protection/All health authorities | |
| HPV vaccination in schools and society for girls aged 13–26 years to prevent cervical cancer | Coverage rate of the targeted category | |||
| Strategic Axis | Ⅲ. Early Detection | |||
| Main objectives | Application mechanisms | Measurement indicators | The executing agency | Follow-up |
| Create a national program for early detection of cancer | Development of a central public electronic recall system for early detection services and identification by e-mail |
|
Ministry of Health and Prevention Society/Childhood Department Maternity/Statistics Department and research |
Ministry of Health and Prevention the society |
| Create a national platform or program for registration of cases that underwent early examination for cancer | ||||
| Increase the capacity of logistical and human resources to increase population coverage | ||||
| Health insurance and financial coverage for early disclosure |
|
Completion rate | ||
| Increase awareness about the importance of early detection |
|
|
Ministry of Health and Prevention (Community/Participants) |
Ministry of Health and Prevention |
| Establish a framework and governance policy for quality assurance and early screening services in the health regions |
|
Percentage of policy completion and frameworks | Ministry of Health and Prevention community/care management Specialty |
|
| Raising awareness of common symptoms of cancer in society | Awareness campaigns about the symptoms of the most common cancers in the community | Number of awareness campaigns | All participating parties | |
| Strategic Axis | Ⅳ. Rapid Diagnosis | |||
| Main objectives | Application mechanisms | Measurement indicators | The executing agency | Follow-up |
| Establish an effective referral system between different levels of care for cancer patients |
|
|
Service providers, Early examination and Therapeutic services |
Ministry of Health and Prevention Participating parties |
| Rapid lung cancer diagnosis initiative | Launch of rapid mobile investigation clinics for early detection of lung cancer using X-ray, CT scan, and breath examination for people susceptible to lung cancer | Number of beneficiaries | Entities involved in cooperation With AstraZeneca |
|
| Strategic Axis | Ⅴ. Treatment | |||
| Main objectives | Application mechanisms | Measurement indicators | The executing agency | Follow-up |
| Covering the cost of cancer treatment | Adopt a Pay for performance model (Personalized reimbursement model). Dubai health authority is providing therapeutic services where the treatment is covered by insurance and pharmaceutical companies. The results are then evaluated on treatment response/efficacy | Number of beneficiaries | Healthcare service providers | Ministry of Health and Prevention Participating parties |
| Accreditation of centers of excellence for cancer treatment | Preparing for specialized centers of excellence (third level) in cancer treatment and its complications and rehabilitation centers | Number of accredited centers of excellence | Stakeholders | |
| Strategic Axis | Ⅵ. Ongoing Care | |||
| Main objectives | Application mechanisms | Measurement indicators | The executing agency | Follow-up |
| Development of palliative care services |
|
|
Ministry of Health and Prevention Stakeholders |
Ministry of Health and Prevention Participating parties |
|
|
Stakeholders | ||
| Strategic Axis | Ⅶ . Performance Measurements | |||
| Main objectives | Application mechanisms | Measurement indicators | The executing agency | Follow-up |
| Annual evaluation for anti-cancer performance indicators |
|
The percentage of completion of the national registry, population coverage for early cancer screening among the targeted age groups | Ministry of Health and Prevention Department of Research and Statistics Participating parties |
Ministry of Health and Prevention Department of Research and Statistics |
|
The percentage of completion of the national cancer registry | Ministry of Health and Prevention Society/Statistics Department of Research and Statistics Participating parties |
Ministry of Health and Prevention Department of Research and Statistics |
|
Measuring indications:
|
Report completion percentage rate of time commitment to access the service |
Ministry of Health and Prevention Participating parties |
Ministry of Health and Prevention community/care management Specialty |
|
|
Report completion rate | Ministry of Health and Prevention Participating parties |
Ministry of Health and Prevention community/care management Specialty |
|
| Strategic Axis | Ⅷ . Research | |||
| Main objectives | Application mechanisms | Measurement indicators | The executing agency | Follow-up |
| The priority for epidemiological and clinical research of cancer | Research work to discover concepts, knowledge and opinions about cancer, risk factors, and screening cancer in the context of encouraging research related to cancer |
Research completion rate | Ministry of Health and Prevention Participating parties |
Ministry of Health and Prevention community/care management Specialization/Management Statistics and research |
| Develop a research agenda for the three most common cancers (breast, colon, and thyroid) | Agenda completion rate | Ministry of Health and Prevention Participating parties |
||
| Strategic Axis | Ⅸ . Workforce | |||
| Main objectives | Application mechanisms | Measurement indicators | The executing agency | Follow-up |
| Providing qualified human resources in the developing field of cancer | Complete medical team specialized in treatingcancer in secondary and specialty care
|
The percentage of increase in workforce | Ministry of Health and Prevention Participating parties |
Ministry of Health and Prevention community/care management Specialty |
| Raising the efficiency of employees, healthcare professionals | Creation of training programs for healthcare workers in the field of cancer and assess the risk factors such as:
|
The number of training programs | Ministry of Health and Prevention Community/Training Center and development Participating parties |
|
4. Vistas in the Cancer Control Plan
4.1. Expected Cancer Burden
The reported age-standardized cancer incidence in the UAE is low compared to the United States and other developed countries. There is, however, a real expectation to have an increment of cancer cases by 10–15% annually, keeping in sight existing cancer trends [2,3,5,6,7,8,11].
4.2. Cancer Control Program
An all-inclusive Cancer Control Program is mandatory to formulate strategy, implement prevention, and enforce a comprehensive cancer management through a collaborative process between government organizations, community, and non-government organizations (NGO). An effective and well-balanced plan should steer to risk reduction, early detection, and improved management to enhance survivorship and efficiently reduce the cancer burden.
The Cancer Control Program should be aimed at keeping the incidence rate at its current level or reducing it. A comprehensive national cancer program assesses various ways to control disease and implements most cost-effective and beneficial means for the population. It places emphasis on preventing cancers or detecting cases early at a curable stage and providing maximum possible relief to patients with advanced disease. A well-developed and implemented cancer control program should result in significant risk reduction, increasing early detection, improved treatment, and enhanced survivorship.
We must strengthen the National Cancer Control Committee, with members of the committee representing all stakeholders. We should adhere to the WHO Cancer Control Strategy to have a standard, reproducible, equitable and uniform approach. It is highly desirable to have increased collaboration with other ministries, such as the Ministry of Religious Affairs, Ministry of Education, and media outlets both private and public. We must draw a road map for the steps of adaptation of the WHO strategy based on a local database [8,11,22,23,24].
4.3. Cancer Registry
A cancer registry is the key instrument for any cancer control plan. It can define cancer burden, identify risk factors of cancer, and evaluate the cancer control program itself. A cancer registry can help in cancer control planning and organization through understanding cancer patterns and time trends by gathering epidemiological indicators, such as cancer incidence, mortality, prevalence, stage at diagnosis, and patient survival.
Recently, registry managers from 19 MENA countries reported the presence of 97 population-based, 48 hospital-based, and 24 pathology-based registries. Most population-based registries were well or partially developed. Lack of accurate death records, complete medical records, and communication between stakeholders and deficiencies in trained personnel were critical challenges that were more severe in active conflict zones and neighboring conflict-affected regions. Cancer registration challenges included weak health infrastructure, absence of legislation mandating cancer registration, and disruption of cancer registration because of active conflict and loss of funding [25].
A well-established national cancer registry regularly documents a yearly report on cancer incidence. Cancer registry should collect comprehensive information, such as stage of disease, mortality, and risk factor data. The registry often operates with an insufficient workforce, unavailability of data on patients diagnosed and treated abroad, and noncompliance from non-governmental institutes and medical personnel, and mobility of population [5,6,25,26,27]. To have precise, consistent, dependable, comprehensive, and beneficial cancer registry data, we need to
Establish the Cancer Registry Advisory Committee to participate in the planning of cancer registry activities, provide feedback on the data and reports, and contribute to data dissemination and advocacy for the registry;
Establishing and implementing data quality indicators;
To complete data on cancer stage, mortality, risk factors, and cancer prevalence;
Increase the trained human resources; work on retention of current staff through training more registry staff and to give them technical and financial support to ensure completeness of cancer registration and sustainability of the cancer registry;
Collect more inclusive data on cancers as well as non-morphologically;
Mandatory reporting, by working on legal obligation to notify cancer;
Adjustments of cancer notification form and electronic notification forms;
Seek more collaboration from healthcare providers.
4.4. Indicators for Monitoring
There are many known global Indicators of attainment employed for monitoring and progress of any national cancer control plan. There can be KPIs, with some being well known and some can be developed according to local situations. Examples of improvement include: education, measured by the cancer awareness measure; reduction in the numbers of smokers; increased proportion of stage 1 and 2 breast and colon cancer; increased proportion of patients diagnosed by screening or urgent referral pathways; publication and comparison of 1- and 5-year cancer survival rates; increase in patients with complete care plans in place across the care pathway; decreasing number of patients travelling abroad for treatment; and more patients accessing ongoing care in primary care/community care services [3,4,5,10,11,16,21,24].
4.5. Continuing the Path to Progress and Excellence
Certain progress has been made, but a lot more is needed as the vision for the future of cancer care remains unchanged as an enormous challenge. The UAE will continue to pursue excellence in cancer care by developing complex specialty services and innovative treatments. New, evidence-based approved treatment modalities and technologies, with proven impacts on patient care, will be accessed and incorporated in management strategies. Improvements in the patient experience will be achieved with a focus on the whole pathway of care, which is based upon the WHO Cancer Care Continuum [22,24,25,27].
4.6. Public Education and Understanding
It is an implacable requisite to invest in educating people to understand the importance of prevention, enhance prevention and early detection initiatives, and swift definite diagnosis of cancer. There is a need to improve refutation programs and alleviate myths about cancer. There are myths, such as that cancer appears at specific sites, appears only in late stages, is more common in low-income countries, is always fatal, and that surgery makes it spread quickly. There are multiple stigmas about cancer; people feel uncomfortable discussing cancer, avoid using the word cancer, diagnosis indicates weakness, fear of loss of job, and loss of sexual activity [2,4,26,27].
4.7. Partnership within the Cancer Community
There is a need to develop close associations within the cancer patient’s community with the objectives for enhancing awareness and prevention of cancer, understanding of cancer, sharing experiences, financial support for eligible cancer patients, to coordinate with various stakeholders to organize meetings, seminars, courses, and conferences; and to support research and raising awareness of the disease and its prevention [25,27].
5. Conclusions
The UAE is a growing economy with a substantial burden of cancer, which is expected to increase with consequent morbidity and mortality. There are screening and early detection efforts which are far from target coverage of the intended population. A comprehensive and effective national cancer control plan is always needed to effectively combat cancer. It needs accurate data collection, an efficient and organized cancer registry, and regular monitoring and evaluation of related activities. A UAE cancer control plan was herein proposed, in line with the WHO and EMRO cancer control initiatives and framework, with well-defined objectives and targets. The objectives are to combat cancer, decrease cancer incidence, restrict morbidity and mortality, improve outcomes, and augment the quality of life for cancer patients. In particular, there is a need to continue on the path of progress and excellence. The cancer registry needs to be broadened and given necessary legislative cover. We must introduce our efforts and commitment more in preventive oncology. We have to also incorporate the ever-growing knowledge, ongoing technological development, and newly approved medications as per international data and guidelines based on clinical trials. We should also endeavor to develop clinical pathways and guidelines, employ these, and continuously monitor our cancer services. We need to expand cancer care initiatives with participation of all stakeholders and deliver cancer services with equity and affordability, keeping in mind the issue of cost-effectiveness. There is a need to induct a qualified workforce, improve their skills and expertise by training and continuing education, and monitor their performance. It is essential to prepare and get international accreditations by known world organizations to be continuously on the path of progress.
The cancer care services must also be accessible with equity, reproducibility, and affordability. Appropriate distribution of resources can enhance delivery of cancer care, often at the patient’s doorstep. We need to integrate and link primary healthcare, secondary care hospitals, tertiary care, and private cancer care centers. The focus should be on development and investing in preventive oncology by boosting education, screening and early detection. The pathways of the patient journey from symptoms to definite treatment need to be thoroughly worked in line with local realities and international guidelines and protocols.
Abbreviations
EMRO: Eastern Mediterranean Region; ICER: Institute for Clinical and Economic review; KPI: key performance indicators; MENA: Middle East and North Africa; MDT: multi-disciplinary team; NICE: National Institute for Health and Care Excellence; NCD: non-communicable diseases; UAE: United Arab Emirates; WHO: World Health Organization.
Author Contributions
Conceptualization, writing, review and editing, supervision, funding acquisition: H.O.A.-S., A.M.A., S.R. All authors have read and agreed to the published version of the manuscript.
Funding
The publication fees of the manuscript was funded by Amgen without any influence on manuscript contents. The manuscript was developed solely by the authors.
Institutional Review Board Statement
Ethical review and approval were waived for this study, due to review type of the study.
Conflicts of Interest
H.O.A.-S. received research funding from Roche pharmaceutical, Amgen and Merck pharmaceutical. The remaining authors declare no conflicts of interest.
Footnotes
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.World Health Organization . National Cancer Control Programs: Policies and Managerial Guidelines. 2nd ed. World Health Organization; Geneva, Switzerland: 2002. [(accessed on 30 October 2021)]. Available online: http://www.who.int/cancer/media/en/408.pdf. [Google Scholar]
- 2.Towards a Strategy for Cancer Control in the Eastern Mediterranean Region, WHO Regional Office for the Eastern Mediterranean WHO EMRO 2009. [(accessed on 30 October 2021)]. Available online: https://applications.emro.who.int/docs/EMROPUB_2019_NCD_EN_23548.
- 3.Radwan H., Hasan H., Ballout R.A., Rizk R. The epidemiology of cancer in the United Arab Emirates. Medicine. 2018;97:e13618. doi: 10.1097/MD.0000000000013618. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Regional Framework for Action on Cancer Prevention and Control Executive Summary (2017), WHO Regional Committee for the Eastern Mediterranean Sixty-Fourth Session Provisional Agenda Item 3(a). EM/RC64/3 September 2017. [(accessed on 30 October 2021)]. Available online: https://applications.emro.who.int/docs/RC_technical_papers_2017_3_20037_en.
- 5.Cancer Incidence in United Arab Emirates-Annual Report of the UAE-National Cancer Registry—2016 and Statistics and Research Center. [(accessed on 30 October 2021)]; Available online: https://www.mohap.gov.ae.
- 6.National Cancer Registry (UAE) The Statistics & Research Dept—National Disease Registry Section. Year List. 2017, 2016, 2015, 2014, 2013, 2012, Report. [(accessed on 30 October 2021)]; Available online: https://smartapps.moh.gov.ae/ords.
- 7.Country Profile United Arab Emirates. [(accessed on 30 October 2021)]. Available online: https://www.who.int/nmh/countries/are_en.pdf.
- 8.Shihab M. Economic Development in the UAE. In: Abed I.A., Hellyer P., editors. United Arab Emirates: A New Perspective. Trident Press Ltd.; London, UK: 2001. pp. 249–260. [Google Scholar]
- 9.United Arab Emirates National Bureau of Statistics Population Estimates 2006–2010. [(accessed on 30 October 2021)]; Available online: http://www.fcsa.gov.ae/
- 10.Henry C.J.K., Lightowler H.J., Al-Hourani H.M. Physical activity and levels of inactivity in adolescent females ages 11-16 years in the United Arab Emirates. Am. J. Hum. Biol. 2004;16:346–353. doi: 10.1002/ajhb.20022. [DOI] [PubMed] [Google Scholar]
- 11.Alwan A. World Health Organization Ethics and health research in WHO Regional Office for the Eastern Mediterranean. East. Mediterr. Health, J. 2016;22:3. doi: 10.26719/2016.22.1.3. [DOI] [PubMed] [Google Scholar]
- 12.Ng S.W., Zaghloul S., Ali H., Harrison G., Yeatts K., El-Sadig M., Popkin B.M. Nutrition transition in the United Arab Emirates. Eur. J. Clin. Nutr. 2011;65:1328–1337. doi: 10.1038/ejcn.2011.135. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Ng M., Fleming T., Robinson M., Thomson B., Graetz N., Margono C., Mullany E.C., Biryukov S., Abbafati C., Abera S.F., et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: A systematic analysis for the Global Burden of Disease Study. Lancet. 2014;384:766–781. doi: 10.1016/S0140-6736(14)60460-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Maziak W., Ben Taleb Z., Bahelah R., Islam F., Jaber R., Auf R., Salloum R.G. The global epidemiology of waterpipe smoking. Tob. Control. 2015;24:i3–i12. doi: 10.1136/tobaccocontrol-2014-051903. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Brauer M., Freedman G., Frostad J., Van Donkelaar A., Martin R., Dentener F., Van Dingenen R., Estep K., Amini H., Apte J., et al. Ambient Air Pollution Exposure Estimation for the Global Burden of Disease. Environ. Sci. Technol. 2016;50:79–88. doi: 10.1021/acs.est.5b03709. [DOI] [PubMed] [Google Scholar]
- 16.Al-Othman S., Haoudi A., Alhomoud S., Alkhenizan A., Khoja T., Al-Zahrani A. Tackling cancer control in the Gulf Cooperation Council Countries. Lancet Oncol. 2015;16:e246–e257. doi: 10.1016/S1470-2045(15)70034-3. [DOI] [PubMed] [Google Scholar]
- 17.United Arab Emirates The National Guidelines for Breast Cancer Screening and Diagnosis (2014)—Ministry of Health & Prevention. [(accessed on 30 October 2021)]; Available online: https://www.mohap.gov.ae.
- 18.Sabih W.K., Taher J.A., El Jabari C., Hajat C., Adib S.M., Harrison O. Barriers to breast cancer screening and treatment among women in Emirate of Abu Dhabi. Ethn. Dis. 2012;22:148–154. [PubMed] [Google Scholar]
- 19.The National Guidelines for Colorectal Cancer Screening and Diagnosis (2014)—Ministry of Health & Prevention. United Arab Emirates. [(accessed on 30 October 2021)]; Available online: https://www.mohap.gov.ae.
- 20.The National Guidelines for Cervical Cancer Screening and Diagnosis (2014)—Ministry of Health & Prevention. United Arab Emirates. [(accessed on 30 October 2021)]; Available online: https://www.mohap.gov.ae.
- 21.Loney T., Aw T.-C., Handysides D.G., Ali R., Blair I., Grivna M., Shah S.M., Sheek-Hussein M., El-Sadig M., Sharif A.A., et al. An analysis of the health status of the United Arab Emirates: The ‘Big 4’ public health issues. Glob. Health Action. 2013;6:20100. doi: 10.3402/gha.v6i0.20100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.United Nations General Assembly . Political Declaration of the High-Level Meeting of the General Assembly on the Prevention and Control of Noncommunicable Diseases. United Nations; New York, NY, USA: 2011. [Google Scholar]
- 23.Beaglehole R., Bonita R., Alleyne G., Horton R., Li L., Lincoln P., Mbanya J.C., McKee M., Moodie A., Nishtar S., et al. UN High-Level Meeting on Non-Communicable Diseases: Addressing four questions. Lancet. 2011;378:449–455. doi: 10.1016/S0140-6736(11)60879-9. [DOI] [PubMed] [Google Scholar]
- 24.World Health Organization National Cancer Control Programmes (NCCP) 2018. [(accessed on 30 October 2021)]. Available online: http://www.who.int/cancer/nccp/en/
- 25.Abdul-Sater Z., Shamseddine A., Taher A., Fouad F., Abu-Sitta G., Fadhil I., Saab R., Sullivan R., Adib S.M., Saleh S., et al. Cancer Registration in the Middle East, North Africa, and Turkey: Scope and Challenges. JCO Glob. Oncol. 2021;7:1101–1109. doi: 10.1200/GO.21.00065. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Fidler M.M., Gupta S., Soerjomataram I., Ferlay J., Steliarova-Foucher E., Bray F. Cancer incidence and mortality among young adults aged 20–39 years worldwide in 2012: A population-based study. Lancet Oncol. 2017;18:1579–1589. doi: 10.1016/S1470-2045(17)30677-0. [DOI] [PubMed] [Google Scholar]
- 27.Fadhil I., Alkhalawi E., Nasr R., Fouad H., Basu P., Camacho R., Alsaadoon H. National cancer control plans across the Eastern Mediterranean region: Challenges and opportunities to scale-up. Lancet Oncol. 2021;22:e517–e529. doi: 10.1016/S1470-2045(21)00410-1. [DOI] [PubMed] [Google Scholar]
